Mylan Says It’ll Pay $465M To United States For Underpaying Medicare Rebates

Mealey's (October 10, 2016, 12:32 PM EDT) -- HERTFORSHIRE, U.K. — Mylan N.V. on Oct. 7 said it has agreed to pay $465 million to settle “questions” by the U.S. Justice Department and other government agencies that the company misclassified its EpiPen epinephrine autoinjector as a generic drug to pay the government less under the Medicaid Drug Rebate Program.

In a Form 8-K filed with the U.S. Securities and Exchange Commission, Mylan said it expects to enter into a corporate integrity agreement with the Inspector General’s Office of the U.S. Department of Health and...
To view the full article, register now.